Related Experiment Video

Updated: May 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection

Jennifer A Flemming1, Norah A Terrault

  • 1Department of Medicine, Viral Hepatitis Center, University of California San Francisco, Room S-357, 513 Parnassus Avenue, San Francisco, CA 94143, USA.

Infectious Disease Clinics of North America
|October 23, 2012
PubMed

Insights

Many patients with hepatitis C virus genotype 1 (GT1) do not respond to protease inhibitor-triple therapy. This review offers a framework for alternative treatment decisions in these experienced GT1 patients.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus genotype 1 (GT1) infection is a global health concern.
  • A significant number of treatment-experienced patients fail to achieve sustained virologic response (SVR) with current protease inhibitor-based triple therapies.
  • The need for effective alternative treatment strategies for these non-responders is critical.

Purpose of the Study:

  • To critically evaluate existing data on treatment options for GT1 patients.
  • To identify knowledge gaps in current therapeutic approaches.
  • To provide a practical framework for guiding treatment decisions in treatment-experienced GT1 patients using approved drugs.

Main Methods:

  • Critical review and synthesis of available clinical trial data.
  • Analysis of treatment outcomes in previously treated GT1 patients.
  • Evaluation of drug efficacy and safety profiles.

Main Results:

  • Protease inhibitor-triple therapy demonstrates suboptimal efficacy in a substantial proportion of treatment-experienced GT1 patients.
  • Significant knowledge gaps exist regarding optimal sequencing and combination of therapies.
  • Current approved drugs offer potential alternatives, but require careful patient selection.

Conclusions:

  • Alternative therapies are essential for treatment-experienced GT1 patients who do not achieve SVR.
  • A structured approach is needed to navigate treatment choices.
  • Further research is required to optimize therapeutic strategies and improve SVR rates.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...